KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer (2016)
- Authors:
- USP affiliated authors: SILVA, ALFREDO RIBEIRO DA - FMRP ; OLIVEIRA, HARLEY FRANCISCO DE - FMRP ; TIRAPELLI, DANIELA PRETTI DA CUNHA - FMRP ; GARCIA, SERGIO BRITTO - FMRP ; FERES, OMAR - FMRP ; ROCHA, JOSE JOAQUIM RIBEIRO DA - FMRP ; PERIA, FERNANDA MARIS - FMRP
- Unidade: FMRP
- DOI: 10.3233/CBM-160592
- Subjects: BIOMARCADORES; NEOPLASIAS DO COLON; METÁSTASE NEOPLÁSICA; CÉLULAS-TRONCO; MOLÉCULAS DE ADESÃO CELULAR
- Keywords: Colon cancer; KRAS mutation; Cancer stem cell; Biomarker
- Language: Inglês
- Imprenta:
- Source:
- Título: Cancer Biomarkers
- ISSN: 1574-0153
- Volume/Número/Paginação/Ano: v. 16, n. 4, p. 513-521, 2016
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
RIBEIRO, Karen Bento et al. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer. Cancer Biomarkers, v. 16, n. 4, p. 513-521, 2016Tradução . . Disponível em: https://doi.org/10.3233/CBM-160592. Acesso em: 02 abr. 2026. -
APA
Ribeiro, K. B., Zanetti, J. da S., Ribeiro-Silva, A., Rapatoni, L., Oliveira, H. F. de, Tirapelli, D. P. da C., et al. (2016). KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer. Cancer Biomarkers, 16( 4), 513-521. doi:10.3233/CBM-160592 -
NLM
Ribeiro KB, Zanetti J da S, Ribeiro-Silva A, Rapatoni L, Oliveira HF de, Tirapelli DP da C, Garcia SB, Féres O, Rocha JJR da, Peria FM. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer [Internet]. Cancer Biomarkers. 2016 ; 16( 4): 513-521.[citado 2026 abr. 02 ] Available from: https://doi.org/10.3233/CBM-160592 -
Vancouver
Ribeiro KB, Zanetti J da S, Ribeiro-Silva A, Rapatoni L, Oliveira HF de, Tirapelli DP da C, Garcia SB, Féres O, Rocha JJR da, Peria FM. KRAS mutation associated with CD44/CD166 immuoexpression as predictors of worse outcome in metastic colon cancer [Internet]. Cancer Biomarkers. 2016 ; 16( 4): 513-521.[citado 2026 abr. 02 ] Available from: https://doi.org/10.3233/CBM-160592 - Clinical-pathological correlation of KRAS mutation status in metastatic colorectal adenocarcinoma
- CHK2 immunohistochemical expression in colon cancer and its relation with clinicopathological features and outcome in metastatic colon cancer patients
- Transanal endoscopic operation for rectal cancer after neoadjuvant therapy
- Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors
- Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer
- Comparative evaluation of oncologic outcomes in colon cancer
- CHK2 expression as predictor factor of tumor aggressiveness and shorter survival in metastatic colon cancer patients
- Fatigue in patients with colorectal cancer treated with capecitabine and oxaliplatin
- Toxicidade aguda no tratamento neoadjuvante de neoplasia de reto utilizando radioterapia e capecitabina
- Hyperbaric oxygen therapy reduces COX-2 expression in a dimethylhydrazine-induced rat model of colorectal carcinogenesis
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
